Research in contextEvidence before this studyWe searched PubMed for articles published in any language about the effect of blood-brain barrier (BBB) damage seen on magnetic resonance imaging (MRI) of aneurysmal subarachnoid hemorrhage (aSAH) patients on risk for long-term neurological deficit. We used the search terms "blood-brain barrier", "BBB", "Magnetic Resonance Imaging", "MRI", "subarachnoid hemorrhage", "SAH", "lesion", "edema", "ischemia", "infarction", "outcome", "eGOS", "GOS", "Glasgow Coma Scale", and "Glasgow Outcome Scale". Our last search was done on September 18, 2018. We found only one pilot work that was published on 6 March 2018. It reported that in a small cohort of patients (*n* = 16), blood-brain barrier (*BBB*) permeability imaging could predict the occurrence of delayed cerebral ischemia within 14 days of aSAH. No quantitative assessment of delayed cerebral ischemia was provided. Overall, we found no reports that provide quantitative characterization of the dynamics of *BBB* dysfunction together with quantified dynamics of brain pathology and clinically-based assessment of disease progression in patients with acute aSAH.Added value of this studyThis study used a large multicenter cohort of 1643 brain MR images from 124 aSAH patients imaged sequentially for over 6 months, to test the potential of quantitative *BBB* imaging as a prognostic and diagnostic biomarker for disease progression and neurological outcome. The strength of our study is the use of imaging-based quantitative approaches for a better understanding of the pathogenesis of neurological complications following brain injury within the clinical setting. For the first time, we identify apparently normal brain voxels that show a leaky barrier and are at risk to become pathological. We further show that a significant *BBB* pathology can be detected as early as 24--48 h after the acute injury. *BBB* pathology was most likely found in the apparently normal brain tissue surrounding the pathological brain, indicating that this adjacent tissue is at the highest risk for delayed injury. Importantly, we found *BBB* pathology to persist for months after the insult and was significantly more extensive in patients with a progressive disease, anatomically (MRI-based) and functionally (clinical outcome). This is the first study to propose a clinically applicable, quantitative approach for MRI imaging that detects microvascular pathology for early prediction of patients\' outcome with high sensitivity and specificity. Since similar pathogenic mechanisms are involved in other brain injuries, we suggest imaging of *BBB* pathology as a potential novel diagnostic and predictive biomarker in brain injuries.Implications of all the available evidenceDue to high mortality and morbidity, accurate prognosis of aSAH patients is crucial for the identification of patients at high risk for delayed neurological complications. Specifically, there is an unmet need for biomarkers that are related to disease pathophysiological mechanisms and may be monitored during treatment. We describe, for the first time, that a leaky *BBB*, detected as early as 24--48 h after the acute event, is associated with disease progression. We propose *BBB* pathology as a potential early biomarker for the identification of patients at high risk for disease complications and progression. Our study lays the foundation for a novel prognostic utility, employing MRI-based quantitative analysis, to significantly improve the capacity of the widely used grading systems to identify patients at high risk for disease progression. Our study suggests investigating microvascular pathology a leaky BBB as potential novel therapeutic targets in brain injury.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating brain insult associated with high morbidity and mortality. The incidence of aSAH is at 9·1 cases per 100,000 patient years \[[@bb0005]\] with a death rate of 40--50% \[[@bb0010]\]. Of those who survive, \>40% will have long-term neurological sequelae, and less than a fifth will have no residual symptoms \[[@bb0015]\]. Due to the high mortality and morbidity rates, understanding the pathophysiology of delayed neurological complications following aSAH and identification of measurable associated biomarkers are crucial for the detection of patients at high risk for such complications, testing novel treatments and improving outcome \[[@bb0020]\].

Cerebral edema is often seen in CT or MR images of patients with aSAH and other types of brain injuries. Brain edema is a predominant cause of poor clinical outcome. The two main types are cytotoxic and vasogenic edema \[[@bb0025]\]; the latter is primarily attributed to breakdown and dysfunction of the blood-brain barrier (*BBB*) \[[@bb0030]\]. *BBB* dysfunction (*BBBD*) has been described within hours after aSAH and has been linked with pathologic changes such as brain edema, thrombosis, inflammation and abnormal cerebral metabolism \[[@bb0035], [@bb0040], [@bb0045], [@bb0050]\]. *BBBD* has also been associated with delayed ischemia in aSAH patients \[[@bb0055]\], and the development of epilepsy and neurodegeneration after traumatic brain injury \[[@bb0060],[@bb0065]\]. Accumulating pre-clinical data show that prolonged breakdown of the *BBB* underlies astroglial activation, neuroinflammation, neural network reorganization, dysfunction and degeneration \[[@bb0060],[@bb0070],[@bb0075]\]. These data suggest *BBBD* as a potential early prognostic biomarker after brain injury. Previously, *BBB* function was assessed either using statistical comparison between images acquired before and after injection of the normally non-permeable gadolinium-based contrast agent \[[@bb0080],[@bb0085]\], or by dynamic studies following the kinetics of gadolinium brain concentrations \[[@bb0090], [@bb0095], [@bb0100], [@bb0105]\]. However, such assessment has not yet been introduced in the routine clinical setting, and the hypothesis on the role of *BBBD* in complications after injury has not been challenged.

Along with *BBBD*, MR imaging in brain injured patients is often characterized by the appearance of abnormal brain tissue (*ABT*), which reflects cytotoxic or vasogenic edemas, gliosis or hemorrhage. Our main goal in the present study was to quantitatively characterize the dynamics of *BBB* dysfunction following aSAH, and assess its prognostic value using imaging- and clinically-based measures for disease progression. To this end, we developed an MRI-based quantitative approach for the identification of brain voxels with apparent *ABT* and *BBBD*. We implemented our approach in 1643 brain MR images from 124 aSAH patients. To our knowledge, this is the first study to quantitatively assess *ABT* dynamics and the potential of *BBB* dysfunction as a predictive biomarker.

2. Materials and methods {#s0025}
========================

2.1. Study design {#s0030}
-----------------

The study was designed and performed as a longitudinal sub-study within the framework of the Co-Operative Studies of Brain Injury Depolarizations (COSBID). Patients with aSAH were selected from a prospectively collected database using pre-specified criteria and endpoints, as described below. The protocol was approved by the ethics committees of the Charité University Medicine Berlin, the Goethe-University Frankfurt, the University Hospital Heidelberg and the University of Cologne. Research was conducted in accordance with the Declaration of Helsinki. Patients or their legal representative gave written consent for study inclusion. Results are reported in accordance with the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines.

Prospective inclusion criteria for aSAH patients in COSBID have been described elsewhere \[[@bb0110]\]: (i) age (≥18 years); (ii) World Federation of Neurosurgical Societies (WFNS) grade I--V; (iii) ruptured saccular aneurysm proven by computed tomography (CT)-angiography or digital subtraction angiography; (iv) symptom onset within the preceding 72 h; and (v) either surgical treatment of the aneurysm via craniotomy or, in coiled patients, burr hole trepanation for placement of a ventricular drain or oxygen sensor, which allows the simultaneous placement of a subdural electrode strip \[[@bb0115]\]. Exclusion criteria were subarachnoid hemorrhage due to other causes (e.g., trauma, fusiform or mycotic aneurysm), admission in a clinical state with unfavorable prognosis (e.g., wide, nonreactive pupils for \>1 h), bleeding diasthesis or pregnancy, unavailability of the monitoring equipment and refusal of the patient or legal representative to participate in the study.

For the present study, patients were retrospectively screened for the availability of at least two serial MRI scans including a T2-weighted fluid-attenuated inversion recovery (FLAIR) sequence, a T1-weighted (T1w) 3D high-resolution sequence (i.e. magnetization prepared rapid gradient echo), a diffusion weighted imaging (DWI) sequence, and T1w sequences before and 5 min after the injection of gadolinium-DTPA (Gd-DTPA 0·5 M, 0·1 mmol/kg).

One hundred twenty-four patients enrolled between January 2007 and March 2016 met criteria, including 50 at Campus Virchow Klinikum, 44 at Campus Benjamin Franklin (Charité University Medicine Berlin), 18 at the Goethe-University Frankfurt, 6 at the University of Cologne and 6 at the University Hospital Heidelberg.

Retrospective analysis of MR images was performed blindly on 377 examinations from the 124 aSAH patients, as well as on images from 21 healthy controls. Each patient had between two and four MRI examination visits and was imaged sequentially for \>6 months. Details of the sequences are provided in appendix Table 1.

Since the longitudinally collected imaging datasets of aSAH patients accommodated an unequal number of follow-up scans per subject and unequal time intervals between scans, we categorized scans according to the time windows after aneurysm event as follows: acute: 24--48 h (*t1*), sub-acute: 3--9 days (*t2*), delayed: 10--19 days (*t3*), and late, around one year (267·6(196·6--358·2); range of 59--1472 days) (*t4*) after the initial hemorrhage. Availability of clinical data and the number of imaging sets available for analysis at each time point are presented in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}.Table 1Clinical data: Demographic data, characteristics of disease and intervention[a](#tf0005){ref-type="table-fn"}.Table 1*eGOS* ≤ 5 *(n* *=* *69, 61*·*6%)*[b](#tf0010){ref-type="table-fn"}*eGOS* *\>* *5 (n* *=* *43, 38*·*4%)*[b](#tf0010){ref-type="table-fn"}*OR (95% CI)p-valuePC (n* *=* *78, 62*·*9%)NPC (n* *=* *46 37*·*1%)OR (95% CI)p-valueSex*0·67570·5524Female4631..5133..Male2312..2713..*Neurological score at admissionWFNS* *≥* *4*46144·14 (1·84--9·32)0·000549173·31 (1·46--6·52)0·0018*WFNS* *\<* *4*23292931*RMS* *\>* *4*63239·13 (3·26--25·57)0·000068274·79 (1·97--11·61)0·0004*RMS*≤*4*6201019*Aneurysm location*[c](#tf0015){ref-type="table-fn"}0·76950·8350ACA32..32..MCA2615..2918..ICA34..44..ACoP116..126..ACoA2114..2514..PeriA01..01..BCA30..30..PICA21..21..*Type of intervention*0·76310·5683Clipping60390·68 (0·20--2·37)68420·65 (0·19--2·20)Coiling94104*Presence of vasospasm*0·29460·1347V-1712..1916..V−/+2118..2317..V+3113..3613..*Arterial hypertension*[d](#tf0020){ref-type="table-fn"}0·00130·0153True40133·69 (1·63--8·39)42162·46 (1·15--5·27)Not true25303230*Anemia*[d](#tf0020){ref-type="table-fn"}0·02660·0309True1733·98 (1·06--15·00)1833·77 (1·01--14·01)Not true37264327*Abnormal liver enzymes*[d](#tf0020){ref-type="table-fn"}0·46880·3716True198..238..Not true3819..4119..*Uric acid*[d](#tf0020){ref-type="table-fn"}0·50210·2708Below normal2411..299..Normal1910..2010..*Total cholesterol*[d](#tf0020){ref-type="table-fn"}0·96860·9811Evaluated12..12..Normal3817..4315..*Previous aSAH*1·00001·0000True01..01..Not true6942..7845..[^2][^3][^4][^5][^6]Table 2Quantitative imaging data as related to clinical outcome[‡](#tf0025){ref-type="table-fn"}.Table 2*eGOS* ≤ 5*eGOS* *\>* *5n of eGOS* ≤ 5*, n of eGOS* *\>* *5OR (95% CI)p-valueAUC (95% CI)PCNPCn of PC, n of NCOR (95% CI)p-valueAUC (95% CI)Age, years*57·00 (48·00--65·00)52·00^⁎^ (44·00--59·00)69, 431·06 (1·02--1·10)0·02610·62 (0·51--0·73)57·00 (48·00--65·00)52·00^⁎^ (44·00--60·00)78, 461·04 (1·00--1·07)0·03510·62 (0·51--0·73)*WFNS*4 (2--5)2^⁎^ (1--4·5)69, 431·60 (1·22--2·11)0·00070·66 (0·55--0·77)4 (2--5)2 (1--4·5)^⁎^78, 461·56 91·21--2·01)0·00050·65 (0·55--0·75)*RMS*7 (5--8)5^⁎^ \[[@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\]69, 431·73 (1·33--2·24)0·0002*0·75 (0·65--0·85)*7 (5--8)5^⁎^ \[[@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]\]78, 461·52 (1·22--1·90)0·0002*0·71 (0·62--0·81)*  *ABT volume, mlABT*~*1*~85·24 (58·95--131·88)55·82 (34·79--98·11)69, 431·01 (1·00--1·02)0·04010·67 (0·58--0·79)84·31 (54·69--131·57)56·25 (35·19--102·02)78, 461·01 (1·00--1·02)0·04100·66 (0·57--0·79)*ABT*~*2*~111·46† (80·47--219·23)68·05^⁎^ (33·05--105·38)42, 241·02 (1·01--1·04)0·0040*0·74 (0·62--0·88)*109·88† (80·47--219·23)67·46^⁎^ (33·05--115·15)47, 251·02 (1·01--1·03)0·0045*0·74 (0·62--0·87ABT*~*3*~134·98† (91·94--199·37)59·75^⁎^ (28·68--93·24)62, 371·02 (1·01--1·040·0002***0·83 (0·74--0·92)***134·55† (91·42--205·27)61·39^⁎^ (30·71--102·64)71, 401·02 (1·01--1·03)0·0003***0·80 (0·71--0·89****ABT*~*4*~138·71† (102·79--204·39)29·55^⁎^† (15·78--73·55)36, 331·03 (1·02--1·05)0·0002***0·88 (0·81--0·97)***138·66† (99·23--204·39)29·55^⁎^† (16·92--71·70)37, 331·03 (1·02--1·05)0·0002***0·88 (0·80--0·96***  *NBT volume, mlNBT*~*1*~1496·3[‡](#tf0025){ref-type="table-fn"} (1359·1--1568·5)1461·8[‡](#tf0025){ref-type="table-fn"} (1370·5--1530·8)69, 43··0·7218··1503·0[‡](#tf0025){ref-type="table-fn"} (1401·2--1575·0)1455·6[‡](#tf0025){ref-type="table-fn"} (1364·4--1522·0)78, 46··0· 4101··*NBT*~*2*~1425·2[‡](#tf0025){ref-type="table-fn"} (1349·7--1534·9)1452·0[‡](#tf0025){ref-type="table-fn"} (1384·1--1515·1)42, 24··0·4159··1425·7[‡](#tf0025){ref-type="table-fn"} (1350·1--1534·9)1440·8[‡](#tf0025){ref-type="table-fn"} (1377·1--1515·1)47, 25··0·5738··*NBT*~*3*~1383·3†[‡](#tf0025){ref-type="table-fn"} (1276·6--1480·7)1451·4[‡](#tf0025){ref-type="table-fn"} (1373·2--1531·6)62, 37··0·0869··1390·0 †[‡](#tf0025){ref-type="table-fn"} (1287·5--1495·1)1442·5[‡](#tf0025){ref-type="table-fn"} (1366·6--1521·4)71, 40··0·0908··*NBT*~*4*~1347·4†[‡](#tf0025){ref-type="table-fn"} (1198·6--1411·8)1475·5^⁎^[‡](#tf0025){ref-type="table-fn"} (1410·8--1542·3)36, 330·99 (0·98--1·00)0·0025***0·81 (0·70--0·91)***1351·8† [‡](#tf0025){ref-type="table-fn"} (1198·6--1437·0)1469·3^⁎^[‡](#tf0025){ref-type="table-fn"} (1389·9--1537·0)37, 330·99 (0·99--1·00)0·00550·77 (0·66--0·89)  *LV volume, mlLV*~*1*~36·59[‡](#tf0025){ref-type="table-fn"} (22·59--57·57)35·13[‡](#tf0025){ref-type="table-fn"} (23·18--48·08)69, 43··0·7216··33·81[‡](#tf0025){ref-type="table-fn"} (20·36--51·44)35·18[‡](#tf0025){ref-type="table-fn"} (23·81--49·51)78, 46··0·9792··*LV*~*2*~34·30[‡](#tf0025){ref-type="table-fn"} (18·44--50·59)27·86 (21·31--37·19)42, 24··0·8668··30·47[‡](#tf0025){ref-type="table-fn"} (17·92--49·00)27·52[‡](#tf0025){ref-type="table-fn"} (21·31--37·19)47, 25··0·9723··*LV*~*3*~40·04[‡](#tf0025){ref-type="table-fn"} (22·00--60·38)35·87[‡](#tf0025){ref-type="table-fn"} (22·00--54·46)62, 37··0·2754··38·29[‡](#tf0025){ref-type="table-fn"} (23·10--60·27)36·32[‡](#tf0025){ref-type="table-fn"} (27·60--54·46)71, 40··0·8910··*LV*~*4*~68·29†[‡](#tf0025){ref-type="table-fn"} (47·98--108·98)45·62^⁎^†[‡](#tf0025){ref-type="table-fn"} (32·07--69·85)36, 331·02 (1·00--1·03)0·01530·67 (0·54--0·8071·51†[‡](#tf0025){ref-type="table-fn"} (50·90--109·39)44·69^⁎‡^ (30·77--56·16)37, 331·03 (1·01--1·05)0·0012*0·74 (0·62--0·86)*  *SAS volume, mlSAS*~*1*~267·08[‡](#tf0025){ref-type="table-fn"} (154·80--379·21)228·55[‡](#tf0025){ref-type="table-fn"} (150·32--344·57)69, 43··0·2901··257·66[‡](#tf0025){ref-type="table-fn"} (148·10--354·18)246·45[‡](#tf0025){ref-type="table-fn"} (160·75--377·70)78, 46··0·8161··*SAS*~*2*~159·26† (107·35--296·91)195·45 (147·68--298·13)42, 24··0·3408··157·28† (104·13--296·91)196·00 (147·69--319·27)47, 25··0·2162··*SAS*~*3*~231·66[‡](#tf0025){ref-type="table-fn"} (154·20--337·51)233·05[‡](#tf0025){ref-type="table-fn"} (145·36--349·60)62, 37··0·6926··221·41[‡](#tf0025){ref-type="table-fn"} (148·19--333·90)257·89[‡](#tf0025){ref-type="table-fn"} (187·68--401·95)71, 40··0·5036··*SAS*~*4*~447·19†[‡](#tf0025){ref-type="table-fn"} (272·10--564·83)361·93^⁎^†[‡](#tf0025){ref-type="table-fn"} (281·57--481·77)36, 33··0·1223··450·92†[‡](#tf0025){ref-type="table-fn"} (272·10--564·83)363·43^⁎^†[‡](#tf0025){ref-type="table-fn"} (281·57--497·71)37, 33··0·1584··  *ABTBBBD volume, mlABTBBBD*~*1*~19·23 (9·53--24·57)11·72^⁎^ (9·08--22·17)49, 301·06 (1·01--1·11)0·01090·68 (0·55--0·80)23·02 (12·01--31·08)12·13^⁎^ (9·23--22·83)59, 341·05 (1·01--1·09)0·01770·66 (0·54--0·78)*ABTBBBD*~*2*~27·60† (14·83--48·23)19·20^⁎^ (8·68--25·24)32, 181·05 (1·01--1·10)0·01840·69 (0·52--0·86)39·11† (19·06--60·50)18·80^⁎^ (7·82--24·73)35, 201·06 (1·01--1·11)0·0088*0·72 (0·56--0·88)ABTBBBD*~*3*~35·88† (23·77--56·47)14·55^⁎^ (8·84--36·32)50, 281·05 (1·02--1·08)0·0004*0·79 (0·68--0·90)*44·14† (28·15--71·10)15·54^⁎^ (8·83--37·41)58, 301·05 (1·02--1·08)0·0002*0·78 (0·67--0·89)ABTBBBD*~*4*~19·91 (13·12--43·18)5·90^⁎^† (2·89--13·8723, 211·07 (1·02--1·13)0·0071***0·85 (0·73--0·97)***24·38 (18·23--50·99)5·84^⁎^† (2·89--11·33)24, 221·08 (1·02--1·14)0·0077***0·85 (0·73--0·97)***  *NBTBBBD volume, mlNBTBBBD*~*1*~127·05[‡](#tf0025){ref-type="table-fn"} (109·78--160·60)106·70^⁎‡^ (62·94--128·60)49, 301·02 (1·01--1·04)0·0017*0·73 (0·61--0·82)*129·47[‡](#tf0025){ref-type="table-fn"} (111·38--161·72)102·08^⁎‡^ (65·53--127·64)59, 341·03 (1·01--1·04)0·0003*0·73 (0·62--0·84)NBTBBBD*~*2*~135·41a (90·94--180·24)90·94^⁎^[‡](#tf0025){ref-type="table-fn"} (64·84--115·12)32, 181·03 (1·01--1·05)0·0086***0·80 (0·64--0·94)***140·32[‡](#tf0025){ref-type="table-fn"} (104·34--191·58)90·23^⁎^[‡](#tf0025){ref-type="table-fn"} (62·70--102·74)35, 201·04 (1·02--1·07)0·0019***0·84 (0·71--0·97)****NBTBBBD*~*3*~127·72[‡](#tf0025){ref-type="table-fn"} (102·66--167·98)94·63^⁎^[‡](#tf0025){ref-type="table-fn"} (72·22--110·45)50, 281·02 (1·01--1·04)0·0016*0·77 (0·65--0·88)*127·72[‡](#tf0025){ref-type="table-fn"} (102·66--167·98)94·63^⁎^[‡](#tf0025){ref-type="table-fn"} (70·52--109·71)58, 301·03 (1·01--1·05)0·0002*0·77 (0·66--0·88)NBTBBBD*~*4*~105·61†[‡](#tf0025){ref-type="table-fn"} (79·18--146·66)69·87^⁎^†[‡](#tf0025){ref-type="table-fn"} (54·99--97·62)23, 211·03 (1·01--1·05)0·0114*0·75 (0·61--0·90)*110·68†[‡](#tf0025){ref-type="table-fn"} (79·21--147·64)67·52^⁎^†[‡](#tf0025){ref-type="table-fn"} (54·99--92·29)24, 221·04 (1·01--1·07)0·0031*0·79 (0·65--0·93)*  *ABTBBBD*^*10*^*volume, mlABTBBBD*~1~^10^42·19 (28·51--60·71)29·19^⁎^ (17·29--46·95)49, 301·04 (1·01--1·06)0·0092*0·66 (0·53--0·78)*45·78 (28·68--65·18)29·63^⁎^ (18·58--45·26)59, 341·04 (1·01--1·06)0·0077*0·67 (0·54--0·79)ABTBBBD*~2~^10^51·74 (38·48--72·96)28·42^⁎^ (15·92--47·61)32, 181·05 (1·01--1·08)0·0076*0·77 (0·62--0·93)*55·58 (40·57--74·87)28·42^⁎^ (13·77--43·44)35, 201·09 (1·04--1·16)0·0001***0·81 (0·67--0·95)****ABTBBBD*~3~^10^52·14 (34·98--74·48)28·11^⁎^ (17·88--38·96)50, 281·04 (1·01--1·06)0·0022*0·76 (0·65--0·88)*52·14 (34·98--74·48)28·11^⁎^ (17·82--39·98)58, 301·05 (1·02--1·07)0·0004*0·76 (0·64--0·87)ABTBBBD*~4~^10^36·67† (24·35--54·67)9·98^⁎^† (6·65--23·52)23, 211·08 (1·03--1·14)0·0012***0·85 (0·73--0·97)***36·66† (24·74--54·31)9·47^⁎^† (6·65--20·89)24, 221·09 (1·04--1·16)0·0009***0·87 (0·76--0·98)***  *ABTBBBD*^*20*^*volume, mlABTBBBD*~1~^20^38·89 (29·32--47·82)27·50 (20·35--48·14)49, 301·02 (0·99--1·05)0·0824*0·61 (0·48--0·74)*39·16 (30·12--48·89)30·41^⁎^ (21·07--42·53)59, 341·03 (1·00--1·06)0·0264*0·64 (0·52--0·76)ABTBBBD*~2~^20^35·51 (30·21--50·70)28·61^⁎^ (16·60--34·74)32, 181·06 (1·01--1·12)0·0225*0·76 (0·53--0·87)*35·59 (27·83--50·98)25·02^⁎^ (15·84--34·51)35, 201·09 (1·03--1·16)0·0040*0·77 (0·60--0·91)ABTBBBD*~3~^20^33·71 (26·32--44·09)25·64^⁎^ (17·03--32·99)50, 281·06 (1·02--1·11)0·0049*0·74 (0·58--0·83)*33·71 (25·42--44·35)25·64^⁎^ (16·70--30·37)58, 301·07 (1·03--1·12)0·0013*0·74 (0·59--0·83)ABTBBBD*~4~^20^34·60 (29·37--50·75)18·39^⁎^ (7·76--30·01)23, 211·08 (1·02--1·14)0·0039*0·79 (0·65--0·92)*34·69 (29·73--50·28)17·94^⁎^† (7·76--28·12)24, 221·10 (1·03--1·17)0·0017***0·82 (0·67--0·95)***[^7][^8][^9]

2.2. Clinical data {#s0035}
------------------

Obtained data included location of aneurysm; type of intervention; vasospasm identification; history of arterial hypertension, anemia on admission anemia on admission defined as total hemoglobin \<14 g/dl in males and \< 12 g/dl in females, abnormal liver enzymes on admission defined as alanine aminotransferase (ALT) \>45/34 U/L (male/female), aspartate aminotransferase (AST) \>50/35 U/L or gammaglutamyl transferase (GGT) \>55/38 U/L; history of previous aSAH; [World Federation of Neurosurgical Societies](https://radiopaedia.org/articles/www.wfns.org){#ir0005} (WFNS) scale \[[@bb0120]\] and Rosen-Macdonald Score (RMS) \[[@bb0125]\] at admission and extended Glasgow Outcome Scale (eGOS) measured at *t4*, as mentioned above. Significant proximal vasospasm (V+) was defined using Doppler sonography, if mean velocity was \>200 cm/s in at least one middle cerebral artery (MCA). Vasospasm (V-) was excluded if the MCA mean velocities remained \<120 cm/s and was defined as possible/not excluded (V−/+) when mean velocity was between 120 and 200 cm/s \[[@bb0130]\]. WFNS and RMS data on admission were categorized into favorable (WFNS\<4, RMS ≤ 4) or poor (WFNS≥4, RMS \> 4). Poor outcome was defined as eGOS≤5 (severe disability or death) and favorable outcome as eGOS\>5 (no or moderate disability).

2.3. Image analysis {#s0040}
-------------------

MR images (including T1w, FLAIR and DWI sequences) were automatically segmented into apparently normal brain tissue (*NBT)* in the combined gray matter (*GM*) and white matter (*WM*), lateral ventricles (*LV*) and subarachnoid space (*SAS*), or *ABT* comprising apparently abnormal signal, reflecting cytotoxic or vasogenic edema, gliosis or hemorrhage. Image processing methods, including multimodal normal tissue and *ABT* segmentation, *BBB* permeability evaluation, and *ABT* vicinity analysis, are provided in the appendix. Prediction of *ABT* volume at long-term outcome, assessment of *BBBD* persistency over time, and evaluation of *BBBD* predictive properties in *ABT* progression and long-term clinical outcomes are provided in the appendix.

2.4. Patient classification based on imaging-detected loss of normal brain tissue in consecutive scans {#s0045}
------------------------------------------------------------------------------------------------------

Because intracranial volume is fixed, the increase in *ABT* and/or enlargement of *LV* and *SAS* were associated with decrease in *NBT* volume. Such decrease in consecutive scans was attributed to disease "progressive course" (*PC*), while no change, or increase in *NBT* volume was considered as a "non-progressive course" (*NPC*) (see appendix).

2.5. Statistical analysis {#s0050}
-------------------------

Quantitative and ordinal data are presented as median with interquartile range and categorical variables are presented as values and percentages. The χ^2^ and Fisher\'s exact (employing Monte Carlo method) tests (for contingency table \>2 × 2) were used to analyze categorical variables. The Wilcoxon rank-sum test was used to analyze continuous independent variables between two groups. A non-parametric Kruskal--Wallis test was performed for continuous independent variables to test the overall multiple group (\>2) differences. The Wilcoxon sign-rank test and Friedman test were used for comparison of dependent variables. When the overall comparisons between different time points were significant, post-hoc tests for multiple comparison correction were performed using Bonferroni procedure. Univariate-logistic regression analysis was used to identify possible risk factors for outcomes of aSAH and odds ratios including 95% confidence intervals were presented. The possible risk factors were included in the multivariate logistic regression analysis for outcomes prediction. Variable selection (forward, inclusion *p* = .05, exclusion *p* = .10) was applied. Receiver operating characteristic (ROC) analysis was performed to assess the diagnostic accuracy of outcome prediction models \[[@bb0135]\]. The level of significance was 0.05 (two-sided) in all analyses.

3. Results {#s0055}
==========

3.1. Clinical findings, demographics and outcome of aSAH patients {#s0060}
-----------------------------------------------------------------

Overall, clinical, demographic and imaging data were analyzed from 124 aSAH patients, including 84 women (67·7%) and 40 men, admitted to 5 medical centers between 2007 and 2016 (appendix, Table 1). Mean age of patients was 55·2 ± 11·3 years (range, 22--79 years). We also scanned 21 healthy control subjects, 28·1 ± 14·7 years (range, 19--46 years). Females were significantly older at the time of admission compared to males (56 (49--64) vs. 50 (44--60·5) years, *p* \< 0·001, Wilcoxon test). The most frequent locations of aneurysm were middle cerebral artery (MCA) (47/124, 37·9%), anterior communicating artery (ACoA) (*n* = 39, 31·5%) and posterior communicating artery (*n* = 18, 14·5%). Among females, most were along the MCA (45·2% compared to 22·5% in males, *p* = 0·025, χ2 test), while ACoA aneurysms were more common in males (50·0% compared to 22·6% in females, *p* = 0·004, χ2 test). Other locations showed no statistically significant difference between both genders (*p* \> 0·4, χ2 test). Near-significant association was found between age and aneurysm location (*p* = 0·063, Kruskal-Wallis, patients with MCA aneurysm were younger 51 (46--59) years, than patients with anterior communicating artery (ACA) aneurysm 69 (59--72) years, *n* = 5). Patients were either treated with surgical clipping (110, 88·7%) or coiling (14, 11·3%). No statistically significant relationships were found between the intervention type and age (*p* \> 0·4), gender (*p* = 0·377, χ2 test), aneurysm location (*p* \> 0·7, Fisher\'s test) or presence of vasospasm (*p* \> 0·4, Fisher\'s test).

No statistically significant relationships were found between WFNS score on admission and gender (*p* = 0·294, χ2 test), age (*p* = 0·305, Wilcoxon test), aneurysm location (*p* = 0·680, Fisher test), type of treatment (*p* = 0·333, χ2 test) or presence of vasospasm (*p* = 0·264, Fisher test). Similarly, no statistically significant relationships were found between RMS score on admission and gender (*p* = 0·771, χ2 test), aneurysm location (*p* = 0·299, Fisher test), or presence of vasospasm (*p* = 0·472, Fisher test). However, RMS was related to patient age (*p* \< 0·001, Wilcoxon test).

Patients with a poor outcome (eGOS) were older than those with a favorable outcome (57 (48--65) years vs 52 (44--59) years; *p* = 0·009). No statistically significant relationships were found between eGOS category and aneurysm location (*p* = 0·762, Fisher\'s test), gender (*p* = 0·604, χ2 test), intervention (*p* = 0·660, χ2 test) or presence of vasospasm (*p* = 0·743, Fisher\'s test) ([Table 1](#t0005){ref-type="table"}).

A significant association was found between presence of arterial hypertension and anemia on admission and a poor outcome (*p* = 0·0013 and *p* = 0·0266, χ2 test, correspondently, [Table 1](#t0005){ref-type="table"}).

3.2. Dynamics of intracranial measures {#s0065}
--------------------------------------

Volume of *ABT* was measured longitudinally in 377 imaging sets from 124 patients ([Fig. 1](#f0005){ref-type="fig"} and appendix, Table 2). *ABT* volume in the early scan (*t1*, 24--48 h after event) was similar in females and males; increased with patient age; largest in patients with MCA aneurysms; significantly larger in patients with poor WFNS (*p* = 0·003, Wilcoxon rank-sum test) and in patients with poor outcome ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}). *ABT* volume at *t4* (\>6 months after event) was not significantly associated with age or aneurysm location and was significantly larger in patients with poor WFNS and with poor eGOS (*p* = 0·0002, [Table 2](#t0010){ref-type="table"}). Overall, *ABT* volume significantly increased with time ([Fig. 1](#f0005){ref-type="fig"}f). As expected, change in *ABT* volume was inversely correlated with the volume of *NBT* (*p* \< 0·006). Interestingly, volume of CSF compartments (lateral ventricles and SAS*)* significantly increased only at *t4* (*p* \< 0·001, [Fig. 1](#f0005){ref-type="fig"}d-e). No significant differences were found between patients who were surgically clipped or coiled (*p* \> 0·6, Wilcoxon rank-sum test).Fig. 1Dynamics of brain MR findings during follow-up.a. Representing MR scans during follow-up. Detected abnormal brain tissue (*ABT*) in red contour. *BBBD* enhancement maps (*BBBDEM*) were created by reassigning each voxel with *BBBD* its enhancement level. The final *BBBDEM* was normalized to 0--1 range (minimal to maximal enhancement level).b. Bar graph showing composition of skull-peeled volume of interest at different time point during follow-up. Normal brain tissue (*NBT* - white); *CSF* sub-arachnoid space (*SAS* - blue); Lateral ventricles (*LV* -green); *ABT* - red. Note the gradual reduction in *NBT* during follow-up.c. Box plot showing mean *NBT* volumes in aSAH patients over time. Note a significant decrease beginning \~2 weeks after the event (*p* = 0·002, Friedman).d, e. Volume of *LV* (D) and *SAS* (E) showing a significant increase at *t4* (*p* \< 0·001, Friedman).f. *ABT* volume significantly increased in aSAH patients at all time intervals in comparison to *t1* (*p* \< 0·02). *NBT* and *ABT* volumetric changes followed a logarithmic pattern (R^2^~adj~ = 0·82(0·76--0·99) for brain volume and R^2^~adj~ = 0·81(0·78--0·97) for *ABT* volume (*p* \< 0·01); correlation between model intercept (*Co*) and *NBT* and *ABT* sizes were correspondently: R^2^ = 0·96 (*p* = 0·02) and R^2^ = 0·88 (*p* = 0·01)). Dynamic of *ABT* and *BBBD* in a subgroup with all four time points is presented in Supplementary Fig. 3.g. Brain volume with *BBBD* within the "abnormal" brain (*ABTBBBD*) significantly increased in *t2* and *t3* compared to *t1* followed by a significant reduction at *t4* (lilac color). *BBBD* within the *NBT* (brown color) was 3·2 (0·8--10·8) fold greater compared to that in healthy controls at all the investigated time intervals *t1-t4* (*p* \< 0·001). Notably, brain volume with BBBD within the *NBT* persisted during the first two week after the acute bleeding event and was significantly reduced only at *t4* (*p* \< 0·01). Overall, *NBT* brain volume with *BBBD* was larger compared to that measured in controls at all-time points.Control data are represented by horizontal solid (median) and dash (third and first quartiles) lines.†Significant difference (*p* ≤ 0·05) between time points (Friedman test followed the Bonferroni procedure).\*Significant difference (*p* ≤ 0·05) between control and aSAH patients at a single time point (Wilcoxon rank sum test).*ABT* = abnormal brain tissue; aSAH *=* aneurysmal subarachnoid hemorrhage; *BBBD* = blood brain barrier damage; *ABTBBBD* = blood brain barrier damage measured in abnormal brain tissue volume; *NBTBBBD* = blood brain barrier damage measured in normal brain tissue volume; *LV* = lateral ventricles; *NBT* = normal brain tissue; *SAS* = subarachnoid space.Fig. 1

3.3. BBB dysfunction {#s0070}
--------------------

Contrast-enhanced MRIs from 104 patients (total of 282 scans) were used to detect brain voxels with *BBBD* (Supp. Figure and [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}a). Interestingly*,* most voxels with *BBBD* were found within the apparently healthy brain ([Fig. 1](#f0005){ref-type="fig"}g), indicating that despite abnormal contrast enhancement, this brain tissue does not show a pathological signal in routine MR sequences (including T1w, FLAIR and DWI). *BBBD* within the apparently healthy brain voxels was most commonly found within a 1-cm ring surrounding lesion cores ([Fig. 2](#f0010){ref-type="fig"}m).Fig. 2Different BBB dynamics in patients with progressive vs non-progressive disease course.a. Representing MR images from aSAH patients with a progressive (*PC*) and non-progressive (*NPC*) disease course. *BBBD* enhancement maps (*BBBDEM*, color bar) are superimposed. Red contour demarcates detected abnormal brain tissue (*ABT*) and green contour demarcates lateral ventricles (*LV)*. *BBBDEM* were created by reassigning each voxel with *BBBD* its enhancement level. The final *BBBDEM* was normalized to 0--1 range (minimal to maximal enhancement level).b. Based on measurements of changes in normal brain tissue (*NBT*) volume over time, patients were classified as having either a "progression course" (*PC*), in which *NBT* decreased with time (*t2-t4*) compared to the first, acute scan (*t1*) (median slope: −18·75 (−48·92--9·07) ml/ln(days)), or a "non-progression course" (*NPC*), characterized by *NBT* volume change slope of 0·73 (0·06--3·58) ml/ln(days).c. Box plot showing a significant difference in *ABT* growth rate between PC and NPC groups: 13·99 (5·90--36·68) ml/ln(days) vs −3·50 (−6·45--2·09) ml/ln(days); *p* \< 0·001, Wilcoxon test.d. Bar graph showing the distribution in brain volume of NBT (white), subarachnoid space (SAS, blue), *LV* (green) and *ABT* (red) over time in the two patient groups. The increase in *ABT* and/or enlargement of *LV* and *SAS* were associated with decrease in *NBT* volume. The relative contributions of *ABT* growth vs *CSF* enlargement (*LV* *+* *SAS*) to *NBT* atrophy was about 1:2 for *PC* and 1:4 for *NPC* patients.e. A significant increase in *ABT* volume during consecutive scans in *PC* patients (*ABT*~*i*~*/ABT*~*1*~ \> 1, for *i* = 2÷4, *p* \< 0·001; see also [Table 2](#t0010){ref-type="table"}, appendix: Table 2B). In contrast, *NPC* patients displayed non-significant change in *ABT* volume during the first 2 weeks (3 scans) after the acute bleeding event and a significant decrease in *ABT* volume by *t4* (*p* \< 0·007; see also appendix Table 2B).f, g. Significant differences between *PC* and *NPC* groups in both *SAS* volume (f) and *LV* volume (g) were found only in the late (*t4*) scans (*p* \< 0·001, Wilcoxon test; see also [Table 2](#t0010){ref-type="table"}). Note lack of significantly differences between the groups in none of the measures (*ABT*, *LV* or *SAS* volume) during the acute stage.h. Significant difference between the groups in *NBT* volume were seen only in the late (*t4*) scans (*p* \< 0·001; [Table 2](#t0010){ref-type="table"}). In the *PC* group, a significant decrease in *NBT* was detected from \~2 weeks after the event (*p* \< 0·01, Friedman).i, j. Volumes of *BBBD* in both *NBT* (i, *NBTBBBD*) and *ABT* (i, *ABTBBBD*) were persistently and significantly greater in the *PC* group relative to *NPC* group in all time points (*p* \< 0·001, Wilcoxon test, see also [Table 2](#t0010){ref-type="table"}). In both groups, a significant decrease in *NBTBBBD* was seen only by *t4* (*p* \< 0·001, Friedman), whereas *ABTBBBD* increased significantly between *t2-t3* in *PC* group, and decreased significantly by *t4* in *NPC* group (*p* \< 0·001, Friedman). Resolution of *BBBD* to 95% CI values of "healthy controls" (\<47·5 ml) was found only in three patients. All these three patients were in *NPC* group and had *ABT* size significantly smaller than patients with non-resolved *BBBD* throughout the investigation. Overall, *NBTBBBD* volume was larger in both groups compared to that measured in controls at all time points ([Table 2](#t0010){ref-type="table"}).k. Overall, in 62% of aSAH patients brain volume with *BBBD* (*NBTBBBD* + *ABTBBBD*) increased with time (slope: 8·57(2·02--24·64) ml/ln(days)) and in 38% of patients BBBD decreased with time (slope: −8·95(−16·87--5·07) ml/ln(days)).l. Box plot showing a significant difference in *BBBD* growth rate between *PC* and *NPC* groups: 3·93 (−4·44--16·78) ml/ln(days) vs −4·73 (−10·74--1·32) ml/ln(days), *p* = 0·001, Wilcoxon test). Interestingly, while in 64% of the patients from the *PC* group brain volume with BBBD increased with time, in 76% of patients in the *NPC* group *BBBD* decreased with time (*p* = 0·022, χ2 test).m. Box plot of the distribution of *BBBD* in abnormal and apparently normal brain tissue, where it was measured in three regions of interest based on the distance to *ABT* border (in cm). *BBBD* voxels were not distributed equally through all regions (*p* \< 0·001). The highest content of *BBBD* voxels was found within 1 cm of *ABT* (33·58 (23·66--41·18) % of entire *BBBD* volume), whereas the lowest content of *BBBD* voxels was located in *ABT* (16·98 (10·25--26·92) % of entire *BBBD* volume). No significant difference was found in content of *BBBD* between the two remaining regions (1--2 cm and \> 2 cm from *ABT* border): 23·90 (17·17--29·27) % and 25·16 (17·34--35·01) %, correspondently.\*Significant difference (*p* ≤ 0·05) between outcome groups (*PC* vs *NPC*), Wilcoxon sum-rank test.†Significant difference (*p* ≤ 0·05) between time points, Friedman test followed the Bonferroni procedure.*ABT* = abnormal brain tissue; aSAH = aneurysmal subarachnoid hemorrhage; *ABTBBBD* = blood brain barrier damage measured in abnormal brain tissue volume; *NBTBBBD* = blood brain barrier damage measured in normal brain tissue volume; *CI* = confidence interval; *CSF* = cerebrospinal fluid; *LV* = lateral ventricles; *NBT* = normal brain tissue; *SAS* = subarachnoid space.Fig. 2

The extent and volume of brain regions with *BBBD* were not significantly associated with gender (*p* \> 0·09, the Mann-Whitney test), aneurysm location (*p* \> 0·3, Kruskal-Wallis test), or treatment (clipped vs coiled, *p* \> 0·7). *BBBD* within the *ABT* was significantly increased at *t2* and *t3* compared to *t1* and was significantly reduced only in delayed scans (*t4*). Within the apparently normal brain tissue, *BBBD* did not change during the first two weeks after the event (*t1-t3*) and significantly declined only in the late scan (*t4*, *p* \< 0·01, Friedman test, [Fig. 1](#f0005){ref-type="fig"}g). To examine the time course of *BBBD* in specific brain voxels, we calculated the probability of a voxel with *BBBD* to remain permeable. Interestingly, the probability of any brain voxel to display *BBBD* during the first week after the acute bleeding (*P*~1,\ 2~^*BBBD*^=0·370(0·274--0·587)) was not significantly different from that measured during the second week (*P*~2,\ 3~^*BBBD*^=0·382(0·311--0·412)) and significantly lower only at delayed time points, *t3* and *t4* (*P*~3,\ 4~^*BBBD*^=0·238(0·176--0·365)), *p* = 0·005, Friedman test).

To test the predictive value of *BBBD*, we examined the outcome of a *BBB-*disrupted voxel within healthy brain tissue. Results showed that a *NBT* voxel with *BBBD* had a significantly higher probability to become abnormal (*ABT)* compared to a voxel with intact *BBB* (*p* \< 0·001, Wilcoxon rank-sum test, [Table 3](#t0015){ref-type="table"}). These results highlight *BBBD* as a potential early predictive biomarker for brain tissue at risk. While *BBBD* could be found in brain regions distant to the *ABT*, the highest probability of a *BBB*-disrupted voxel (comparably to non-*BBB*-disrupted) to turn into *ABT* was found at a distance of ≤1 cm from the *ABT* (*p* \< 0·001, Kruskal-Wallis, [Table 3](#t0015){ref-type="table"}). In contrast, the probability of a non-*BBBD* voxel to turn into *ABT* was significantly lower compared to a voxel with *BBB* and was not related to distance from *ABT* ([Table 3](#t0015){ref-type="table"}).Table 3Investigation of a voxel fate:Table 3Probability of turnover of a normal brain tissue voxel at *t1* to turn into *ABT* at *t4*:*ABT*^10^*ABT*^20^*ABT*^\>20^*nNBTBBBD*~1~0·284^⁎,⁎⁎⁎^ (0·122--0·594)0·196^⁎^ (0·106--0·412)0·212^⁎^ (0·099--0·464)70$\mathit{NBT}{\overset{\sim}{\mathit{BBBD}}}_{1}$0·089 (0·068--0·141)0·063 (0·045--0·101)0·069 (0·052--0·117)70  Probability of persistence of an abnormal brain tissue voxel with *BBBD* to remain *ABT* at *t4*:*TotalnABTBBBD*~1~0·697 (0·584--0·841)^⁎⁎^70*ABTBBBD*~2~0·721 (0·596--0·838)^⁎⁎^61*ABTBBBD*~3~0·740 (0·630--0·937)^⁎⁎^64  Probability of persistence of an abnormal brain tissue voxel without *BBBD* to remain *ABT* at *t4*:*Totaln*$\mathit{ABT}{\overset{\sim}{\mathit{BBBD}}}_{1}$0·244 (0·102--0·348)70$\mathit{ABT}{\overset{\sim}{\mathit{BBBD}}}_{2}$0·252 (0·121--0·377)61$\mathit{ABT}{\overset{\sim}{\mathit{BBBD}}}_{3}$0·242 (0·114--0·353)64[^10][^11][^12]

3.4. Dynamics of intracranial measures reveals a progressive or non-progressive disease course {#s0075}
----------------------------------------------------------------------------------------------

According to the dynamic changes found in tissue characteristics over time, patients were grouped into a "progressive" and "non-progressive" disease course (*PC* and *NPC*, respectively). *PC* was attributed to patients in whom the healthy brain tissue (*NBT)* volume decreased between the initial and last scan, while *NPC* was attributed to patients in whom the abnormal tissue volume decreased ([Fig. 2](#f0010){ref-type="fig"}b-c). In our cohort, 63% (78/124) of patients were classified as having a *PC* and 37% (46/124) displayed a *NPC*. No differences were found between the groups in distributions of gender, aneurysm location and type of intervention ([Table 2](#t0010){ref-type="table"}). Importantly, the initial early scan (*t1*) did not show differences between the groups in volume of *ABT*, *LV* or *SAS*.

Imaging-based categorization of disease course highly correlated with clinical outcome, as determined by eGOS, with a sensitivity of 98% and specificity of 97%: Forty-two (97·7%) patients with a non-progressive course had favorable eGOS, whereas 67 (97·1%) patients with a progressive course had poor eGOS. Thus, out of 112 patients, only three patients (2·68%) were misclassified: one patient with a gradual increase in the volume of apparently abnormal tissue showed a good outcome (eGOS = 6), and two patients with a decrease in measured abnormal tissue had a poor outcome (eGOS = 5). In contrast, disease course correlated poorly with clinical status on admission (sensitivity = 0·674, specificity = 0·654, appendix Table 3). The correspondence between aSAH course (*PC/NPC* groups) and WFNS categories was 64·5% (80/124 matched), and to RMS categories it was 70·2% (87/124 matched, sensitivity = 0·655, specificity = 0·716).

3.5. BBBD dynamics and clinical course {#s0080}
--------------------------------------

Interestingly, already at the very early scan (*t1*) and in all investigation time points, brain volume with *BBBD* was significantly larger in the progressive course compared to the non-progressive disease course group (*p* = 0·001, Wilcoxon rank-sum test). When correlated with clinical status on admission (WFNS), we found that during all scanning time points, the extent of *BBBD* in abnormal brain tissue (*ABT-BBBD*) was associated with poor WFNS (*p* \< 0·041, Wilcoxon rank-sum test). Notably, at all time points and in both *NBT* and *ABT*, *BBBD* was significantly larger in patients within the poor eGOS group (*p* \< 0·001, Wilcoxon rank-sum test, [Table 2](#t0010){ref-type="table"}).

3.6. Predictive value of clinical and imaging biomarkers with ROC analysis {#s0085}
--------------------------------------------------------------------------

We next used logistic regression models in search of clinical and imaging biomarkers that best predict aSAH outcome. Model fit and ROC analysis results for predicting long-term eGOS are shown in [Table 4](#t0020){ref-type="table"} and [Fig. 3](#f0015){ref-type="fig"}. When only clinical data were used, ROC analysis revealed a "fair" area under curve (AUC) for both models, consisting of either age and WFNS or RMS score only. Prediction was improved with addition of extent of *BBBD* in apparently normal brain tissue (*BBBD-NBT*) and volume of *ABT*.Table 4Models for long-term outcome prognoses:Table 4ModelCoefficientCoefficient Value (SE)OR (95% CI)*pn*AUC (SE)A. Models for prediction course of aSAH[a](#tf0030){ref-type="table-fn"}Ψ~0~^*WFNS*^*β*~*1*~*\*WFNSβ*~*1*~−0·445 (0·129)0·64 (0·50-0·83)0·0011240·673 (0·052)Ψ~0~^*Age*&*WFNS*^*β*~*1*~\*Age + *β*~*2*~*\*WFNSβ*~*1*~−0·034 (0·018)0·97 (0·93-1·00)0·0601240·712 (0·049)*β*~*2*~−0·434 (0·130)0·65 (0·50-0·84)0·001Ψ~0~^*RMS*^*β*~*1*~*\*RMSβ*~*1*~−0·431 (0·113)0·65 (0·52-0·81)0·0001240·719 (0·048)Ψ~1~*β*~*1*~\*NBTBBBD~1~ +*β*~*1*~−0·035 (0·010)0·97 (0·95-0·98)0·000930·829 (0·043)*β*~*2*~ \**RMSβ*~*2*~−0·348 (0·149)0·71 (0·53-0·95)0·020Ψ~2~*β*~*1*~\*NBTBBBD~2~ +*β*~*1*~−0·057 (0·018)0·55 (0·33-0·94)0·030550·905 (0·042)*β*~*2*~\**WFNSβ*~*2*~−0·590 (0·272)0·95 (0·91-0·98)0·001Ψ~3~*β*~*1*~\*NBTBBBD~3~*β*~*1*~−51·697 (13·931)0·00 (0·00-0·00)0·000880·793 (0·049)Ψ~4~*β*~*1*~\*ABT~4~ +*β*~*1*~−0·138 (0·060)0·87 (0·77-0·98)0·022460·979 (0·017)*β*~*2*~\*NBTBBBD~4~ +*β*~*2*~−0·059 (0·027)0·94 (0·89-0·99)0·027*β*~*3*~\*ABTBBBD~4~*β*~*3*~0·298 (0·148)1·35 (1·01-1·80)0·044  B. Models for prediction of eGOS status of aSAH[a](#tf0030){ref-type="table-fn"}:Ψ~0~^*WFNS*^*β*~*1*~*\*WFNSβ*~*1*~−0·471 (0·138)0·63 (0·48-0·82)0·0011120·676 (0·055)Ψ~0~^*Age*&*WFNS*^*β*~*1*~\*Age + *β*~*2*~*\*WFNSβ*~*1*~−0·062 (0·021)0·94 (0·90-0·98)0·0031120·750 (0·050)*β*~*2*~0·484 -(0·144)0·62 (0·47-0·82)0·001Ψ~0~^*RMS*^*β*~*1*~*\*RMSβ*~*1*~−0·564 (0·132)0·57 (0·44-0·74)0·0001120·757 (0·048)Ψ~1~*β*~*1*~\*NBTBBBD~1~ +*β*~*1*~−0·027 (0·009)0·97 (0·96-0·99)0·003790·827 (0·051)*β*~*2*~ \**RMSβ*~*2*~−0·491 (0·168)0·61 (0·44-0·85)0·004Ψ~2~*β*~*1*~\*ABT~2~ + *β*~*2*~\*NBTBBBD~2~*β*~*1*~−0·013 (0·007)0·99 (0·97-1·00)0·073500·871 (0·052)*β*~*2*~−0·030 (0·012)0·97 (0·95-0·99)0·012Ψ~3~*β*~*1*~\*ABTBBBD~3~ +*β*~*1*~−0·044 (0·014)0·96 (0·93-0·98)0·002780·830 (0·048)*β*~*2*~\**RMSβ*~*2*~−0·382 (0·169)0·68 (0·49-0·95)0·023Ψ~4~*β*~*1*~\*ABT~4~ +*β*~*1*~−0·087 (0·030)0·92 (0·86-0·97)0·004440·942 (0·035)*β*~*2*~\*ABTBBBD~4~*β*~*2*~0·156 (0·075)1·17 (1·01-1·36)0·037[^13][^14]Fig. 3Analysis of the predictive value of BBBD measurements in aSAH patients.Receiver operating characteristic (ROC) analysis showing specificity and sensitivity for prediction of aSAH course (a) and of long-term eGOS category (b). Whereas Ψ~0~^*Age*&*WFNS*^ (blue dashed line) and Ψ~0~^*RMS*^ (blue solid line) models contain only clinical data, the remaining models combine clinical data with imaging results at the different time points (*t1-t4*). When only clinical data was used, ROC analysis revealed a "fair" area under the curve (AUC) for the models consisting of either patient age and WFNS score (Ψ~0~^*Age*&*WFNS*^: AUC = 0·712 for (a) and AUC = 0·750 for (b)), or of RMS score only (Ψ~0~^*RMS*^: AUC = 0·719 for (a) and AUC = 0·757 for (b)). Prediction was improved with addition of *t1* time--restricted imaging predictor, i.e. the extent of *BBBD* in apparently normal brain tissue (*NBTBBBD*~1~) and in volume of *ABT*~1~ (*ABTBBBD*~1~) (Ψ~*t1*~: AUC = 0·829 for (a) and AUC = 0·827 for (b)). A better yet prediction was achieved with *t2* time-restricted models (Ψ~*t2*~: correspondently: AUC = 0·905 and 0·871 for (a) and AUC = 0·855 and 0·887 for (b)). The best prediction was achieved with *t4* time-restricted model (Ψ~*t4*~: AUC = 0·979 for (a) and AUC = 0·942 for (b)). While *BBBD* imaging alone revealed a "fair" prediction at t~1~ (AUC = 0·724(0·059) for (a)AUC = 0·726(0·061) for (b)) and a "good" prediction at t~2~ (AUC = 0.867(0.062) for (a)AUC = 0·816(0·073) for (b)).*ABT* = abnormal brain tissue; AUC = area under the curve; aSAH = aneurysmal subarachnoid hemorrhage; *ABTBBBD* = blood brain barrier damage measured in abnormal brain tissue volume; *NBTBBBD* = blood brain barrier damage measured in normal brain tissue volume.Fig. 3

4. Discussion {#s0090}
=============

Cerebral ischemia after aSAH is a cause of substantial morbidity and mortality \[[@bb0140]\]. In the present study, we examined the potential of quantitative imaging, including imaging of *BBBD,* in predicting delayed tissue damage and clinical outcome. In this patient population with severe aSAH \[[@bb0145]\], we found that: (1) Disease progression occurred mostly during the first week, but the volume of abnormal tissue may continue to progress for months after the acute hemorrhagic insult; (2) Imaging-based measurements showing a progressive disease were associated with a worse clinical outcome at \>6 months; (3) Significant *BBB* pathology can be detected as soon as 24--48 h after the acute bleeding, and was found within the apparently normal and abnormal brain tissue; (4) *BBB* pathology was widespread but most likely found in the apparently normal brain tissue surrounding the abnormal brain tissue; (5) *BBB* pathology may persist for months after the insult and was larger in patients with a progressive course; (6) Voxels with *BBBD* within the apparently healthy brain*,* especially those located in close proximity to the *ABT,* were likely to become pathological; (7) Multi-linear regression model revealed a significant power for early detection of *BBBD* in predicting clinical outcome.

Demographic characteristics of the present aSAH cohort were consistent with previous studies. While females were twice more prone to aSAH, they were affected later in life compared to males \[[@bb0150], [@bb0155], [@bb0160], [@bb0165]\]. MCA and anterior communicating artery (ACoA) were the most frequent aneurysm locations, with ACoA aneurysms more frequent in males and MCA aneurysms more frequent in females \[[@bb0155],[@bb0170],[@bb0175]\]. Although coiling has gained acceptance as an alternative to clipping for aSAH treatment, it remains elusive how the two procedures are compared in terms of outcomes \[[@bb0180]\]. In the present cohort, no differences were found between the interventions in imaging- or clinical-based outcome. Investigation of clinical data revealed, that history of hypertension (\~3.7 times is more likely), anemia (\~4 times) and neurological scores WFNS (\~4 times) and RMS (\~9 times) at admission were detected as predictors for a poor clinical outcome.

We present here two novel, independent, semi-automatic and objective image analysis approaches for the identification of brain pathologies. The first was used for the detection and monitoring of brain lesions (*ABT*). Interpretation of abnormal brain tissue after aSAH is particularly challenging because of the multitude of pathological processes. For instance, cytotoxic edema after aSAH may result from the initial global ischemia, intracerebral hemorrhage, early or delayed focal cerebral ischemia, brain retraction or extra-ventricular drainage. In a similar fashion, findings of *BBBD*/vasogenic edema can be the radiological correlate of edema caused by the initial ischemia and reperfusion injury leading to global cerebral edema, subarachnoid blood products, brain retraction during aneurysmal surgery, early or delayed focal cerebral ischemia, chronic white matter lesions or transependymal edema due to hydrocephalus. Therefore, based on multimodal signal intensities, anatomical location, and morphology, we used a general assessment of *ABT* to measure a sum of different pathogenic processes. We validated our approach by comparison to manual segmentation in a subset of aSAH patients (see appendix). Furthermore, the excellent correlation of disease progression with patients\' clinical outcome confirms the validity of our analysis approach. It further suggests that, while most of the tissue damage occurs during the first week after bleeding, disease continues to progress for weeks and months.

Studies aimed at determining reliable biomarkers for the identification of patients at high risk for delayed complications following aSAH have been scarce. DeRooij and collagues \[[@bb0185]\] developed a practical risk chart based solely on easily obtainable admission characteristics. Good clinical condition on admission (WFNS), small amount of extravasated blood and younger age were found to be associated with a low risk of delayed cerebral ischemia. However, the prediction model had poor specificity and sensitivity (AUC \< 0·70). Ayling and colleagues \[[@bb0140]\] found that presence of an early cerebral infarct, poor WFNS and greater subarachnoid clot were associated with poor outcome. However, the ability of early infarction to predict outcomes was also poor (AUC = 0·62). In accordance with previous studies, we found that poor clinical condition on admission and advanced age are the earliest predictors of delayed increase in *ABT* \[[@bb0140],[@bb0185], [@bb0190], [@bb0195], [@bb0200], [@bb0205]\]. In the present study, the predictive value of a model consisting of the significant predictor RMS was fair (AUC = 0·71), greater than WFNS, and comparable to prognostic accuracy of a model combining WFNS with age. We show that MR-based quantitative analysis significantly improves the capacity to identify patients with disease progression (i.e. decline in *NBT*) and poor outcome. Importantly, we found that detection of *BBBD* as early as 24--48 h after the acute event improves model prediction. *BBBD* after aSAH has been described in human \[[@bb0210]\] and in a number of animal studies \[[@bb0215], [@bb0220], [@bb0225]\]. Based on animal experiments, *BBBD* has been suggested to play a key role in neuro-inflammation, astroglial activation and network modification, epileptogenesis and neurodegeneration \[[@bb0060],[@bb0230],[@bb0235]\]. These data suggest a direct link between *BBBD* and long-term outcome.

This is the first clinical study testing the potential of quantitative *BBBD* imaging in identifying patients at-risk for disease progression. We report that *BBBD* is common in aSAH patients and is found in both the apparently healthy and abnormal brain tissue. Our findings are in agreement with pre-clinical experiments showing that disease progression overlaps spatially and follows temporally *BBB* pathology \[[@bb0240]\]. A substantial part of lesions observed after aSAH involves the cerebral cortex \[[@bb0245]\], and lesions typically develop adjacent to subarachnoid blood clots in both animals and humans \[[@bb0250],[@bb0255]\]. Therefore, it has been suggested that subarachnoid blood products are an important pathophysiological elements, likely through constrictive effects on small cortical arteries, depolarizing effects on cortical neurons and astrocytes and disturbed functional coupling between the different cellular elements within the neurovascular unit \[[@bb0260]\]. An additional effect of blood might be *BBB* opening through factors such as potassium and/or hemoglobin released from erythrocytes \[[@bb0265]\]. Thus, as supported by the present study, *BBBD* may serve as an indicator for tissue at risk to develop ischemia in response to subarachnoid blood clots.

We thus suggest BBBD imaging as a potential novel diagnostic and predictive biomarker for tissue at risk to develop ischemia in response to subarachnoid hemorrhage for the following reasons: (1) *BBB* permeability increase can be detected as early as 24 h after the acute insult; (2) Brain volume with *BBBD* is found in patients with a progressive disease, and was the only differentiating factor between the groups at the early time point (*t1*); (3) Apparently normal brain tissue with *BBBD* is likely to become abnormal with time; and (4) Inclusion of early *BBBD* within the normal brain tissue in a regression model improves prediction of outcome. With the accumulation of data on vascular protecting therapy, it is not unlikely that microvascular pathology will become a target for early preventive treatment of patients after brain injury, further stressing the importance of quantitative diagnosis of vascular integrity.

This study had several limitations. First, *ABT*, detected by our algorithm, represents a mixture of different pathophysiological processes, including edema, hemorrhage and scar tissue. Future developments and identification of specific pathologies is expected to increase imaging sensitivity in predicting outcome, shed light on pathophysiological mechanisms in individual patients and offer specific treatment targets. Second, the study design posed difficulties such as unavailability of imaging data for all of the patients at all time points. Third, eGOS data were missing for \~10% of the patients. Only differences in frequencies of about 26% or more could be detected with sufficient power in this study. Nevertheless, despite of small sample size (*n* = 124) this is the first large-scale study within the research field on BBB spatiotemporal course and lesion progression in patients with brain injury, offering new quantitative neuroimaging analysis methods that are informative for patient monitoring and outcome prediction. To conclude, we highlighted micro-vascular pathology and specifically a leaky *BBB* as a potential mechanism underlying disease progression as well as a diagnostic and predictive biomarker. Future prospective studies are awaited to test and validate our approach following traumatic and ischemic brain injuries before contrast-enhanced MRI should be recommended as routine test in patients after brain injuries.
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Supplementary Fig. 1. Abnormal brain tissue quantification.Flowchart describing steps 2 and 3 of the segmentation algorithm (see text for details). The final labeling overlaid T1w image (green, gray matter; blue, white matter; yellow, cerebrospinal fluid; red, abnormal brain tissue (ABT)). GMM = Gaussian mixture model.Supplementary Fig. 2. Quantitative approach for the assessment of BBB pathology.a. Enhancement distribution histograms of three representative regions, namely background (green), muscle (black) and vessel (red), were used to define *BBB* breakdown enhancement range of τ~1~ - τ~2~.;b. BBB damage enhancement map of brain tissue (gray matter + white matter) and lesion (excluding pixels relating to ventricles and subarachnoid space) as defined by enhancement range of τ~1~ - τ~2~.;C. Increased sensitivity *BBB* damage enhancement map. Initial BBB damage was iteratively expended by appending the connected neighbouring voxels that have enhancement in the extended range 0·5τ~1−~1·5τ~2~. *BBB* = blood brain barrier.Supplementary Fig. 3. Dynamic of *ABT* and *BBBD* in a subgroup with all four time points.a. *ABT* volume was not significantly in subgroup of aSAH patients (with all four time points MRI data, *n* = 76) in comparison to entire cohort - 124 aSAH patients (*p* \> 0·11, Wilcoxon sign-rank test, Fig. [1](#f0005){ref-type="fig"}f).;b. *BBBD* volume was not significantly in subgroup of aSAH patients (with all four time points MRI data, *n* = 61) in comparison to entire cohort - 124 aSAH patients (*p* \> 0·16, Wilcoxon sign-rank test).ABT = abnormal brain tissue; aSAH = aneurysmal subarachnoid hemorrhage; BBBD = blood brain barrier damage.Image 1Supplementary material 1Image 2Supplementary material 2Image 3
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[^1]: These authors contributed equally

[^2]: OR = odds ratio. PC = progressive course of aSAH. NPC = non-progressive course of aSAH.

[^3]: Only significant OR values were presented in the table.

[^4]: Neurological outcome (eGOS) was available for 112 (90%) patients.

[^5]: Aneurysms were assessed using four-vessel digital subtraction angiography (DSA).

[^6]: Clinical data were not available for all of the patients.

[^7]: OR = odds ratio. PC = progressive course of aSAH. NPC = non-progressive course of aSAH.

[^8]: Significant difference ≤ 0·05 between outcome groups (*eGOS* ≤ 4*,* vs *eGOS* *\>* *4, or PC* vs *NC)* with Wilcoxon sum-rank test^⁎^. Significant difference ≤ 0·05 between different time points with Friedman test†. Significant difference ≤ 0·05 between control and a measurement at a single time point with Wilcoxon sum-rank test‡. The area under the ROC curve (AUC) results were considered "excellent" for AUC values between 0·9--1, "good" for AUC values between 0·8--0·9, "fair" for AUC values between 0·7--0·8, "poor" for AUC values between 0·6--0·7 and failed for AUC values between 0·5--0·6.

[^9]: Only significant OR values were presented in the table.

[^10]: ^⁎^Significant difference between probabilities of a normal brain tissue (*NBT*) voxel with blood brain barrier damage (*BBBD*) (*NBTBBBD*~*1*~) and without *BBBD* ($\mathit{NBT}{\overset{\sim}{\mathit{BBBD}}}_{1}$) to become an abnormal brain tissue (*ABT*~*4*~) voxel at *t4* (*p* \< 0·05, Wilcoxon sum-rank test).

[^11]: ^⁎⁎^Significant difference between probabilities of *ABT* voxel with *BBBD* (*ABTBBBD*~*j*~) and without *BBBD* ($\mathit{ABT}{\overset{\sim}{\mathit{BBBD}}}_{j}$) to remain an *ABT*~*4*~ voxel at *t4* (where *j* = 1, ...,3 denotes time interval *t1-t3*) (*p* \< 0·05, Wilcoxon sum-rank test).

[^12]: ^⁎⁎⁎^Significant difference between different regions: *ABT*^10^, *ABT*^20^ and *ABT*^\>20^ (*p* \< 0·05, Kruskal-Wallis test).

[^13]: SE = standard error.

[^14]: Uncategorized WFNS and RMS grades were used in the logistic model. Since the neurological grades on admission RMS and WFNS are dependent \[[@bb0125]\] variables, only one of them can be included in the multivariate model at the time.
